ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Fiona Craig

Cobra Resources Expands Boland Project with New Land Acquisition

27 May 2025 @ 18:31
Cobra Resources Plc (LSE:COBR) has announced the acquisition of additional exploration licenses, increasing its landholding for the Boland Rare Earth Project by 36%. This expansion significantly enhances the project’s resource growth potential. Strategically located for low-cost, environmentally friendly in situ recovery (ISR) mining, the new licenses reinforce Cobra’s position in the rare...
 

Georgina Energy Progresses Key Australian Projects

27 May 2025 @ 18:30
Georgina Energy Plc (LSE:GEX) has provided a project update on its Hussar and Mt Winter sites, reporting progress in obtaining drilling approvals and identifying new resource targets. The company is collaborating with regulatory authorities and traditional owners to advance exploration and development, supported by significant engineering and seismic data reprocessing efforts. These...
 

Starwood European Real Estate Finance Schedules 12th Annual General Meeting

27 May 2025 @ 18:29
Starwood European Real Estate Finance Limited (LSE:SWEF) has announced that its Twelfth Annual General Meeting (AGM) will take place on 12 June 2025 in Guernsey. The company has published its Annual Report and Consolidated Financial Statements for the year ended 31 December 2024, accessible on its website and via the National Storage Mechanism. Shareholders are […]
 

Poolbeg Pharma’s POLB 001 Earns FDA Orphan Drug Status

27 May 2025 @ 18:27
Poolbeg Pharma (LSE:POLB) has secured Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration for its oral candidate, POLB 001. The therapy targets prevention of Cytokine Release Syndrome (CRS), a serious immune reaction linked to T-cell engager bispecific antibody cancer treatments. This ODD status offers Poolbeg key advantages including potential market exclusivity and...
 

Software Circle Recovers £426,770 After Suspected Fraud Incident

27 May 2025 @ 18:26
Software Circle plc (LSE:SFT) has successfully retrieved £426,770 following a suspected authorised push payment fraud that targeted one of its subsidiaries. The company credits a coordinated response with its banking partners and involved parties for the rapid recovery. Software Circle reassures investors that the event was isolated, with no compromise to its systems or data, […]
 

4basebio PLC Achieves Robust Growth and Strategic Progress in 2024

27 May 2025 @ 18:23
4basebio PLC (LSE:4BB) reported impressive growth throughout 2024, with DNA sales revenue doubling year-over-year. The company also secured a £40 million equity funding round to accelerate its expansion initiatives. Key achievements last year include supplying synthetic DNA for vaccine clinical trials, gaining a GMP manufacturing license, and establishing a Strategic Advisory Board to guide...
 

Bodycote Reports Revenue Drop but Maintains Positive Outlook for 2025

27 May 2025 @ 18:22
Bodycote plc (LSE:BOY) has released a trading update revealing a 6% decrease in group revenue during the first four months of 2025 compared to the same period last year. This decline is largely due to tough comparisons with the previous year’s strong performance and a reduction in energy surcharges. While the Automotive and Industrial sectors […]
 

HSBC Slightly Boosts Holding in Spirent Communications

27 May 2025 @ 18:20
Spirent Communications PLC (LSE:SPG) has reported an incremental increase in the voting rights held by HSBC Holdings plc, which now stands at 6.032%, up marginally from 6.028%. This adjustment encompasses several HSBC entities, including HSBC Bank plc and HSBC Global Asset Management (UK) Limited. The change highlights HSBC’s continued strategic interest in Spirent, potentially influencing...
 

EU CHMP Recommends Approval of AstraZeneca’s Imfinzi for Bladder Cancer Treatment

27 May 2025 @ 18:18
AstraZeneca (LSE:AZN) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending Imfinzi for approval as the first perioperative immunotherapy for muscle-invasive bladder cancer. This endorsement follows results from the Phase III NIAGARA trial, which demonstrated a marked decrease in disease recurrence and mortality...
 

Conygar Investment Reports Higher NAV and Key Loan Restructuring

27 May 2025 @ 18:17
The Conygar Investment Company PLC (LSE:CIC) has announced a rise in its net asset value, reaching £63.8 million, primarily driven by profitable asset disposals including the sales of Holyhead Waterfront and Parc Cybi. In addition, the company successfully restructured its Barclays development loan, securing more favorable repayment terms and extending the maturity date. This move […]
 
 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com